- Home
- PPBT vs STRR Comparison
PPBT vs STRR Comparison
Compare PPBT & STRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- STRR
- Stock Information
- Founded
- PPBT 2010
- STRR 1985
- Country
- PPBT Israel
- STRR United States
- Employees
- PPBT N/A
- STRR N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- STRR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PPBT Health Care
- STRR Health Care
- Exchange
- PPBT Nasdaq
- STRR Nasdaq
- Market Cap
- PPBT 6.3M
- STRR 6.3M
- IPO Year
- PPBT N/A
- STRR N/A
- Fundamental
- Price
- PPBT $2.62
- STRR $2.13
- Analyst Decision
- PPBT Strong Buy
- STRR Strong Buy
- Analyst Count
- PPBT 1
- STRR 1
- Target Price
- PPBT $33.00
- STRR $5.00
- AVG Volume (30 Days)
- PPBT 30.8K
- STRR 61.6K
- Earning Date
- PPBT 05-21-2025
- STRR 05-14-2025
- Dividend Yield
- PPBT N/A
- STRR N/A
- EPS Growth
- PPBT N/A
- STRR N/A
- EPS
- PPBT N/A
- STRR N/A
- Revenue
- PPBT N/A
- STRR $57,165,000.00
- Revenue This Year
- PPBT N/A
- STRR $33.64
- Revenue Next Year
- PPBT N/A
- STRR $22.87
- P/E Ratio
- PPBT N/A
- STRR N/A
- Revenue Growth
- PPBT N/A
- STRR 34.33
- 52 Week Low
- PPBT $2.00
- STRR $1.72
- 52 Week High
- PPBT $13.95
- STRR $5.35
- Technical
- Relative Strength Index (RSI)
- PPBT 56.64
- STRR 47.17
- Support Level
- PPBT $2.46
- STRR $2.16
- Resistance Level
- PPBT $2.80
- STRR $2.75
- Average True Range (ATR)
- PPBT 0.20
- STRR 0.24
- MACD
- PPBT 0.04
- STRR -0.00
- Stochastic Oscillator
- PPBT 66.96
- STRR 32.80
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About STRR Star Equity Holdings Inc.
Star Equity Holdings Inc is a multi-industry diversified holding company. It operates in two segments: Building Solutions segment, through KBS, EBGL and TT, it services residential and commercial construction projects by manufacturing modular housing units, structural wall panels, permanent wood foundation systems, other engineered wood products, and supply general contractors with building materials; and Investments segment, which holds corporate-owned real estate, currently includes one manufacturing facility and the equipment for another manufacturing facility in Maine that it leases back to KBS and its manufacturing facility in Wisconsin that it leases back to TT. The company derives maximum revenue from Building Solutions Segment.